Targeted Therapy in Advanced Bladder Cancer : What Have We Learned? - 15/04/15
Résumé |
Despite advances in the treatment of other genitourinary malignancies, no novel therapies have been approved by the US Food and Drug Administration for urothelial carcinoma (UC) in the last 20 years. To date, no clinical trials of targeted agents in UC have led to improvements in survival compared with cytotoxic therapy. This article outlines representative trials of targeted therapies in UC and discusses the significance of genetic preselection in trial design as a method to optimize responses to these agents, thus, hopefully expanding the armamentarium of treatment options against this lethal disease.
Le texte complet de cet article est disponible en PDF.Keywords : Urothelial carcinoma, Targeted therapy, Small molecule inhibitors, Next-generation sequencing, Angiogenesis, MAPK pathway, PI3K/Akt/mTOR pathway
Plan
| Disclosure Statement: The authors indicate no conflicts of interest. |
Vol 42 - N° 2
P. 253-262 - mai 2015 Retour au numéro
Article précédent
- Surgical Advances in Bladder Cancer : At What Cost?
- David C. Johnson, Peter S. Greene, Matthew E. Nielsen
- Index
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?